bluebird bio faces imminent bankruptcy unless a deal closes; current offer is $5 cash or $3 plus a low-value CVR. A rival ...

Chris DeMuth Jr., is the founder of Rangeley Capital. Chris runs the investing group Sifting the World, in which he shares his best ideas, deep research, extensive resources and real time updates ...

Everybody, thanks for joining us today. We're going to dive straight into this webinar because there is a lot to unpack with Chris DeMuth Jr. here today. If you don't know who he is, we're going ...

Our guest this week is Hedge Fund Manager Chris DeMuth Jr. Chris shares an update on his big stock pick of 2023, his newest event driven trade, and how investors can play it. He also provides ...

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor.

Usually sure-footed, Christopher DeMuth slips into error when he writes that “American conservatism became unduly attached to libertarian individualism, unfettered ...

Chris DeMuth Jr. emphasizes value investing with a focus on event-driven, mispriced securities, and unique opportunities like demutualizations and litigation situations. He highlights the ...

Chris DeMuth Jr. shares why demutualization presents consistent opportunities, with many banks selling at significant premiums within 3-5 years post-demutualization. Credit unions, being cash-rich ...

Chris DeMuth, Jr. shares some of his current top picks. Arbutus Biopharma is a promising investment due to its potential litigation value from IP claims against Pfizer and Moderna related to COVID ...